

# 1 **Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2** 2 **Infection: Compensatory Responses in a Population-Based Cohort**

3  
4 **Authors:** Dominik Menges<sup>1</sup>†, Kyra D. Zens<sup>1,2</sup>†, Tala Ballouz<sup>1</sup>†, Nicole Caduff<sup>1,2</sup>, Daniel  
5 Llanas-Cornejo<sup>1</sup>, H el ene E. Aschmann<sup>1,3</sup>, Anja Domenghino<sup>1,4</sup>, C eline Pellaton<sup>5</sup>, Matthieu  
6 Perreau<sup>5</sup>, Craig Fenwick<sup>5</sup>, Giuseppe Pantaleo<sup>5</sup>, Christian R. Kahlert<sup>6,7</sup>, Christian M unz<sup>2</sup>, Milo A.  
7 Puhan<sup>1\*</sup>, Jan S. Fehr<sup>1</sup>

## 8 **Affiliations:**

9 <sup>1</sup> Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH),  
10 Zurich, Switzerland.

11 <sup>2</sup> Institute for Experimental Immunology, University of Zurich (UZH), Zurich, Switzerland.

12 <sup>3</sup> Department of Epidemiology, University of California San Francisco, San Francisco, USA.

13 <sup>4</sup> Department of Visceral and Transplantation Surgery, University Hospital Zurich (USZ),  
14 University of Zurich (UZH), Zurich, Switzerland.

15 <sup>5</sup> Service of Immunology and Allergy, Lausanne University Hospital (CHUV), University of  
16 Lausanne (UNIL), Lausanne, Switzerland

17 <sup>6</sup> Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St.  
18 Gallen, Switzerland

19 <sup>7</sup> Division of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern  
20 Switzerland, St. Gallen, Switzerland

21

22 \* Corresponding author. Email: [miloalan.puhan@uzh.ch](mailto:miloalan.puhan@uzh.ch).

23 † These authors contributed equally to this work.

24

25

26 **Abstract:** To better understand the development of immunity against SARS-CoV-2 over time,  
27 we evaluated humoral and cellular responses a population-based cohort of SARS-CoV-2-infected  
28 individuals covering the full spectrum of COVID-19 up to 217 days after diagnosis. We  
29 characterized anti-Spike (S)-IgA and -IgG antibody responses in 431 individuals and found that  
30 about 85% develop and maintain anti-S-IgG responses over time. In a subsample of 64  
31 participants selected for a detailed characterization of immune responses, we additionally  
32 evaluated anti-Nucleocapsid (N)-IgG antibodies and T cell responses specific to viral Membrane  
33 (M), N, and S proteins. Most participants had detectable T cell responses to at least one of the  
34 four peptide pools analyzed, which were more frequent than antibody seropositivity. We found a  
35 moderate correlation between antibody and T cell responses, which declined over time and  
36 suggests important variability in response patterns between individuals. The heterogeneity of  
37 immune trajectories was further analyzed using cluster analyses taking into account joint  
38 antibody and T cell responses over time. We identified five distinct immune trajectory patterns,  
39 which were characterized by specific antibody, T cell and T cell subset patterns along with  
40 disease severity and demographic factors. Higher age, male sex, higher disease severity and  
41 being a non-smoker was significantly associated with stronger immune responses. Overall, the  
42 results highlight that there is a consistent and maintained antibody response among most SARS-  
43 CoV-2-infected individuals, while T cell responses appear to be more heterogenous but  
44 potentially compensatory among those with low antibody responses.

45

46 **One Sentence Summary:** Presence of heterogenous immune response trajectories after SARS-  
47 CoV-2 infection with potential compensatory role of T cells among individuals with low  
48 antibody responses.

49

50 **Main Text:**

51 **INTRODUCTION**

52 Almost two years after its start, the SARS-CoV-2 pandemic remains a threat to public  
53 health worldwide and has resulted in hundreds of million cases and millions of deaths globally  
54 (1). Control of the pandemic now relies largely on the development of robust immunity in the  
55 population after infection, vaccination, or both, which necessitates an in-depth understanding of  
56 humoral and cellular responses to the virus.

57 Several studies have characterized B and T cell-mediated immune responses against  
58 SARS-CoV-2 and showed that both antibodies and T cells are generated in most people after  
59 infection (2–19). Immunoglobulin (Ig) spike specific antibodies have been detected within a few  
60 days after infection (4, 14–16, 19–22) and their neutralizing capacity has been confirmed (5, 12,  
61 14, 18, 22–26), with the magnitude of response positively correlating with disease severity (7,  
62 17, 21, 27–30). However, studies have also shown varying results regarding the longitudinal  
63 changes of these antibody responses. While certain studies found that antibodies persist for  
64 several months after infection (8, 10, 25, 26, 29, 31–37), some reported declining levels of  
65 antibodies within a few months, particularly among those with mild disease (30, 38–42), raising  
66 concerns about the longevity of protection against re-infection. On the other hand, T cell-  
67 mediated immunity generally seems to be more stable. There is some evidence that robust T cell  
68 responses are developed even after mildly symptomatic coronavirus disease 2019 (COVID-19)  
69 or asymptomatic infection and despite low levels or a complete absence of antibodies (8–10, 28,  
70 31, 43, 44). While these studies have significantly advanced the general understanding of  
71 immunological responses after SARS-CoV-2 infection, most were conducted in highly specific

72 populations or using convenience samples. Few have longitudinally assessed the diverse  
73 components of the immune response within the same individuals (2, 8, 28, 31) and in cohorts  
74 representative of the entire range of the infected population (8, 28, 31). Furthermore, despite  
75 evidence of heterogeneous immune responses between individuals and the knowledge that  
76 antibodies and T cells act together at different stages of a viral infection to protect against severe  
77 disease and re-infection, little attention has been paid to capturing or describing the diverse joint  
78 trajectories of antibodies and T cells within individuals infected with SARS-CoV-2.

79         In this study, we analyzed longitudinal patterns of humoral and cellular immune  
80 responses for up to six months post-diagnosis in a population-based cohort of SARS-CoV-2-  
81 infected individuals across the full COVID-19 disease spectrum. We first characterized anti-  
82 Spike (S) IgA and IgG antibody responses and estimated their decay rates up to 217 days post-  
83 diagnosis in 431 individuals. In a subsample of 64 participants selected to cover the full clinical  
84 spectrum of SARS-CoV-2 infection and antibody responses, we performed a detailed evaluation  
85 of anti-Nucleocapsid (N) IgG antibodies and T cell responses specific to viral Membrane (M), N,  
86 or S proteins (including the S1 and the majority of the S2 domains). Based on the co-evolution of  
87 both antibody and T cell responses over time, we defined five distinct immune trajectory patterns  
88 post-infection. Overall, this longitudinal study highlights that there is a consistent antibody  
89 response among most, but not all, SARS-CoV-2-infected individuals up to six months, while T  
90 cell responses appear to be more heterogeneous, but potentially compensatory among those with  
91 low antibody responses.

92

## 93 **RESULTS**

### 94 **Study population and sample measurements**

95            In this analysis, we included measurements from 431 SARS-CoV-2-infected individuals,  
96            selected as a random, age-stratified sample of all SARS-CoV-2-infected individuals reported to  
97            the Department of Health of the Canton of Zurich between 06 August 2020 and 26 January 2021.  
98            Peripheral blood samples were collected for immunological analysis at two weeks, one month,  
99            three months, and six months after diagnosis of infection (Fig. 1A). The median age of  
100            participants was 52 years (interquartile range (IQR) 35–68 years) and 212 (49%) were female  
101            (Supplementary Table S1). Fifty-nine (14%) of the participants were smokers and 131 (30%) had  
102            at least one comorbidity, most commonly hypertension (16%) and respiratory diseases (7%).  
103            Most participants (83%) were symptomatic, with 163 (38%) reporting between one and five  
104            symptoms and 192 (45%) reporting six symptoms or more during acute infection. Within two  
105            weeks of diagnosis, 18 (4%) participants required hospitalization for reasons related to COVID-  
106            19, among which two participants were admitted to an intensive care unit. At six months after  
107            diagnosis, three participants (0.7%) reported a SARS-CoV-2 reinfection and 80 (19%) were  
108            vaccinated with at least one dose (all with mRNA vaccines).

109            We selected a subsample of 64 individuals for a detailed characterization of immune  
110            responses (i.e., additional anti-N antibody testing as well as ELISpot and flow cytometric  
111            analyses of virus-specific T cells), aiming to cover the full spectrum of disease severity (i.e.,  
112            asymptomatic to hospitalized), antibody responses (i.e., low to high anti-S-IgA and -IgG  
113            antibody responses) and balanced in terms of age and sex (Fig. 1B). In this subsample, the  
114            median age was 53.5 (IQR 33.5–68 years) and 56% of participants were female (Supplementary  
115            Table S1). 69% of the participants had symptoms of COVID-19, with 27% reporting between  
116            one and five symptoms and 42% reporting six or more symptoms. Eleven (17%) of the

117 participants were hospitalized due to COVID-19 and one participant required admission to an  
118 intensive care unit.

119 In summary, anti-S antibody responses were characterized in 431 SARS-CoV-2 infected  
120 individuals at two weeks, one month, three months and six months after diagnosis. Anti-N  
121 antibody responses, as well as M-, N-, S1 domain- and S2 domain-specific T cell responses were  
122 additionally measured in a subsample of 64 individuals, covering the full clinical spectrum and  
123 range of S-specific antibody responses at these timepoints.

124

125 **Longitudinal follow-up of patients recovering from COVID-19 highlights sustained anti-**  
126 **Spike IgG responses, anti-Nucleocapsid and anti-Spike Domain 2 T cell responses, and**  
127 **CD8<sup>+</sup> T cell responses**

128 Using a highly sensitive Luminex-based assay (45), we first assessed levels of SARS-  
129 CoV-2 S-specific IgA and IgG or N-specific IgG in blood plasma over time. Within the full  
130 study population (n=431) we found that the median anti-S-IgA response was highest by two  
131 weeks post-diagnosis, after which responses declined steadily up to six months (Fig. 2A,  
132 Supplementary Tables S2 and S3). In contrast, anti-S-IgG responses peaked later at one month  
133 post-diagnosis, persisted until three months, and then waned slightly until the six month follow-  
134 up (Fig. 2B). Among the subsample (n=64) we found that anti-N-IgG responses followed a  
135 similar initial kinetic to that of anti-S-IgG (peaking at month one), but the decline over time was  
136 more pronounced (Fig. 2C). From these data, we utilized a linear decay model adjusted for time  
137 from diagnosis to maximum antibody concentration, to estimate the half-life of each antibody  
138 subtype. From the full population we estimated the half-life of anti-S-IgA to be 71 days (95% CI

139 66–76 days, Fig. 2D) and 145 days (135–156 days; Fig. 2E) for anti-S-IgG. From the subsample,  
140 we estimated the half-life of anti-N-IgG to be 86 days (76–99 days; Fig. 2F).

141 We further evaluated the level of seropositivity for each antibody subtype. In the full  
142 study population, we found that 83% (79–86%) and 82% (78–86%) of individuals were anti-S-  
143 IgA or anti-S-IgG seropositive, respectively at two weeks post-diagnosis (Supplementary Fig.  
144 S1A, Supplementary Table S2). While the percentage of anti-S-IgA-seropositive participants  
145 decreased over time reaching 70% (65–75%) at six months, the percentage remaining anti-S-  
146 IgG-seropositive was more stable (81%, 77–85%). Overall, 85% of the population was positive  
147 for either anti-S-IgA or -IgG at three (81–88%) and six (81–88%) months post-diagnosis. Of  
148 note, only ten participants (2.3%) were initially seropositive (either anti-S-IgA or -IgG) but  
149 became seronegative within six months. Estimates were similar in age group-weighted sensitivity  
150 analyses (Supplementary Table S4). In the subsample, 59% of the participants were seropositive  
151 each for anti-S-IgA and -IgG, and 54% were seropositive for anti-N-IgG at two weeks. At six  
152 months, 61%, 66% and 41% were seropositive for anti-S-IgA, anti-S-IgG and anti-N-IgG,  
153 respectively (Supplementary Fig. S1B, Supplementary Table S3). Taken together, these findings  
154 suggest that S-specific IgG responses are more robust than S-specific IgA or N-specific IgG  
155 responses following SARS-CoV-2 infection.

156 In the subsample, we additionally evaluated virus-specific T cell populations using an  
157 interferon-gamma ELISpot assay, assessing responses to overlapping peptide pools spanning the  
158 entire SARS-CoV-2 M and N proteins, the S1 domain of the S protein (which contains the  
159 Receptor Binding Domain (RBD)), or a mix of other predicted immunodominant epitopes within  
160 the S protein, containing the majority of the S2 domain (which we refer to here as S2 for  
161 simplicity). We found that 84% (72–91%) of individuals had detectable T cell responses to at

162 least one of the four tested peptide pools at two weeks post-infection, dropping to 71% (58–81%)  
163 at six months (Fig. 3A, Supplementary Fig. S1C). Positivity to individual peptide pools ranged  
164 from 71% (59–82%; S2) to 80% (68–89%; M) at two weeks to 46% (33–59%; S1) to 51% (38–  
165 64%; N) at six months, with no discernible differences in positivity between pools at any  
166 timepoint (Fig. 3A, Supplementary Fig. S1C, Supplementary Table S3). Assessing the combined  
167 T cell response to all four peptide pools over time, M-specific T cells made up 33% of the total  
168 detectable T cell response at two weeks of follow-up, compared to 29% S1-specific, 21% N-  
169 specific, and 16% S2-specific T cells (Fig. 3B). Proportions remained stable up to six months,  
170 contributing 26%, 26%, 27% and 21% to the total T cell response, respectively. Similar to  
171 antibody responses, we estimated decay kinetics for individual peptide pool-specific T cell  
172 responses or for the overall T cell response by summing the responses to individual peptide  
173 pools. For the overall T cell response, we estimated a half-life of 145 (80–781) days  
174 (Supplementary Fig. S1D). For individual peptide pools, we estimated the half-life of M and S1-  
175 specific T cells to be substantially shorter (128 days and 126 days, respectively) compared to that  
176 of N and S2-specific T cells (227 days and 266 days, respectively), suggesting that the latter may  
177 provide more durable responses following infection (Supplementary Fig. S1E to S1H).

178 We further evaluated SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the subsample  
179 using a Flow Cytometry-based Activation-Induced Marker (AIM) assay. Using the markers  
180 CD137 (4-1BB) and CD134 (OX-40) for CD4<sup>+</sup> T cells or CD69 and CD137 for CD8<sup>+</sup> T cells, we  
181 determined frequencies of activated cells following in vitro stimulation with a combined pool of  
182 M, N, S1, and S2 peptides (Fig. 3C). We found similar frequencies of total peripheral blood  
183 AIM<sup>+</sup>CD4<sup>+</sup> or AIM<sup>+</sup>CD8<sup>+</sup> T cells (approximately 0.2–0.3%) at two weeks post-diagnosis. For  
184 CD4<sup>+</sup> T cells, this declined over time to 0.1% at six months, although this did not reach statistical



185 significance ( $p=0.11$ , Kruskal-Wallis test; Fig. 3D). In contrast, for  $CD8^+$  T cells, frequencies of  
186  $AIM^+$  cells were more stable over time, remaining at 0.2% up to six months post-infection. In  
187 assessing the phenotype of  $AIM^+$  T cells in the blood,  $CD4^+AIM^+$  T cells were predominantly  
188 central memory T cells (TCM), while  $CD8^+AIM^+$  T cells were predominantly T effector memory  
189 cells re-expressing CD45RA (TEMRA; Fig. 3E). Taken together, our results suggest that,  $CD8^+$   
190 T cells, in addition to anti-S IgG, and M- and S-specific T cells, act as more long-lasting  
191 components of SARS-CoV-2-specific immunity following infection.

192

193 **Sustained, strong concordance within antibody or T cell responses, but moderate**  
194 **concordance between antibody and T cell responses which declines over time**

195 To better understand the relationship within and between antibody and T cell responses  
196 over time, we next used the subsample to evaluate concordance by comparing the levels of  
197 antibody and T cell responses. Within the overall antibody response (anti-S-IgA, -S-IgG, -N-  
198 IgG), we observed a strong, positive correlation in the magnitude of response among different  
199 subtypes at each timepoint post-diagnosis (Fig. 4A). Similarly, within the overall T cell response,  
200 we observed a strong, positive correlation in the magnitude of response among different peptide  
201 pools at each timepoint (Fig. 4A). In comparing between antibody and T cell responses,  
202 however, the correlation was less robust, but still present. At two weeks post-diagnosis, we  
203 observed a weak to moderate, positive correlation between the magnitude of each antibody  
204 subtype evaluated and overall (pooled M, N, S1, S2) T cell responses (anti-S-IgA Spearman  
205  $r=0.38$ ; anti-S-IgG Spearman  $r=0.37$ ; anti-N-IgG Spearman  $r=0.47$ ; Fig. 4A). This correlation  
206 decreased over time and was weak or no longer observed by six months of follow-up (anti-S-IgA  
207 Spearman  $r=0.16$ ; anti-S-IgG Spearman  $r=0.25$ ; anti-N-IgG Spearman  $r=0.24$ ). These findings

208 highlight that antibody and T cell responses tend to behave similarly (in terms of magnitude)  
209 early in the immune response, but not necessarily in the longer term. Furthermore, the magnitude  
210 of the response by one antibody subtype is better predicted by the response to other antibody  
211 subtypes than by T cell responses, and vice versa.

212 We also assessed the proportion of individuals that were “positive” or “negative” for  
213 antibody and T cell responses at each timepoint, comparing anti-S-IgA, anti-S-IgG, or anti-N-  
214 IgG to pooled T cells responses (positive to any peptide pool; Fig. 4B), or to specific peptide  
215 pools (Supplementary Fig. S2A). At two weeks post-diagnosis, approximately 55–60% of  
216 individuals were both antibody “positive” and pooled-T cell “positive”, while approximately 10-  
217 15% were both antibody “negative” and pooled-T cell “negative” (Fig. 4B). Thus, overall  
218 percent concordance between antibody responses and pooled T cell responses was approximately  
219 70%, which was similar for anti-S-IgA, anti-S-IgG, and anti-N-IgG. By six months, concordance  
220 between pooled T cell responses dropped to 55–60% (depending on antibody subtype). For both  
221 anti-S-IgA and anti-S-IgG, this appeared to be primarily due to an increased fraction of  
222 participants becoming T cell “negative”. For anti-N-IgG, this drop appeared to be additionally  
223 driven by an increasing fraction of anti-N-IgG “negative” participants. Patterns of antibody  
224 subtype and T cell concordance were also similar between T cells specific to individual peptide  
225 pools (M, N, S1, S2), and analogous trends were observed when evaluating test agreement using  
226 Cohen's Kappa (Supplementary Fig. S2A and S2B). Together, these findings suggest that SARS-  
227 CoV-2-specific antibody and T cell responses correlate early after infection, but that this  
228 correlation decreases with increasing time after infection.

229

230 **Clustering of antibody and T cell responses reveals five distinct joint immune trajectories**

231 We subsequently explored whether distinct patterns of joint antibody and T cell response  
232 trajectories could be observed using a non-parametric longitudinal clustering algorithm (46, 47).  
233 We identified five distinct joint trajectories of antibody subtypes and peptide pool-specific T cell  
234 responses within the subsample (Fig. 5A and 5B). Clusters of participants were primarily defined  
235 by the presence (clusters 1-4) or absence (cluster 5) of antibody responses, as well as distinct T  
236 cell trajectories. When present, antibody trajectories generally followed the decay patterns  
237 observed in the overall study population, characterized by waning anti-S-IgA and anti-N-IgG as  
238 well as persistent anti-S-IgG. Meanwhile, T cell trajectories between clusters were more  
239 heterogenous. We additionally examined T cell subsets using data from flow cytometric  
240 analyses, which did not influence clustering, to identify differences in immune phenotypes  
241 between clusters.

242 The *first cluster* (14% of subsample participants) was characterized by high antibody and  
243 T cell responses, which remained high across all evaluated timepoints. T cell response  
244 trajectories were similar for M, N, S1, S2 peptide pools, peaking at three months with a  
245 subsequent slight decline up to six months post-diagnosis. N- and S2-specific T cell responses  
246 were the most robust; at six months post-diagnosis, 88% participants had detectable N-specific T  
247 cells and 75% had S2-specific T cells (Fig. 5C, Supplementary Fig. S3A). By flow cytometric  
248 analysis, individuals in cluster 1 had the highest total CD4<sup>+</sup> T cell count at one and three months  
249 post-diagnosis, but showing a decline at six months (Supplementary Fig. S3B). Additionally,  
250 total CD8<sup>+</sup> T cell numbers were lower compared to clusters 3-5 and showed a decline from three  
251 to six months. We further found that individuals in this cluster had higher frequencies of both  
252 CD4<sup>+</sup>AIM<sup>+</sup> and CD8<sup>+</sup>AIM<sup>+</sup> virus-specific T cells at all timepoints compared to all other clusters  
253 except cluster 2 (Fig. 5C). We noted that participants belonging to the first cluster were mostly

254 older than 65 years (89%), male (56%) and 22% were smokers (Fig. 5D). The majority (78%)  
255 had more than six COVID-19 symptoms and 44% were hospitalized within two weeks of  
256 diagnosis, indicating more severe disease. Thus, cluster 1 tended to represent older individuals  
257 with more severe disease and also robust antibody and cell-mediated immune responses.

258       The *second cluster* (12% of the subsample) was characterized by persistently high anti-S-  
259 IgA and -IgG responses in all participants, who also demonstrated a steep increase in virus-  
260 specific T cells from two weeks to one month post-diagnosis. T cell positivity subsequently  
261 declined until six months post-diagnosis, with N- and S2-specific T cells being present in 63%  
262 and 13% of participants, respectively (Fig. 5C, Supplementary Fig. S3A). By flow cytometry, we  
263 found that individuals in this cluster had lower total CD8<sup>+</sup> T cell numbers than those in all other  
264 clusters at two weeks and one months, increasing up to three months post-diagnosis  
265 (Supplementary Fig. S3B). Meanwhile, they peaked in total CD4<sup>+</sup> T cells at one month, which is  
266 consistent with the increase in T cell responses observed by ELISpot analysis between two  
267 weeks and one month after diagnosis (Fig. 5C, Supplementary Fig. S3B). As in cluster 1,  
268 frequencies of CD4<sup>+</sup>AIM<sup>+</sup> and CD8<sup>+</sup>AIM<sup>+</sup> T cells tended to be higher compared to other clusters  
269 (Fig. 5C, Supplementary Fig. S3A). Also similar to cluster 1, most (63%) participants had six or  
270 more symptoms and 25% were hospitalized (Fig. 5D). However, participants in this cluster were  
271 mostly younger than 65 years (63%), female (63%) and non-smokers or ex-smokers (75%).  
272 Thus, cluster 2 was composed mostly of younger females with more severe disease, but robust  
273 antibody responses and T cell responses which may tend towards higher CD4<sup>+</sup> responses.

274       The *third cluster* (19% of the subsample) was characterized by antibody responses which  
275 were initially high, but declined more sharply than in clusters 1-2. Anti-S-IgG, however,  
276 remained detectable in all participants up to the six month follow-up visit. Meanwhile, overall T

277 cell responses initially waned up to three months post-diagnosis, but then increased again for all  
278 peptide pools by month six, at which point 92% of participants had detectable N-specific and S2-  
279 specific T cells (Fig. 5C, Supplementary Fig. S3A). By flow cytometry, individuals in this  
280 cluster tended to have the highest CD8<sup>+</sup> T cell numbers at two weeks compared to other clusters  
281 (Supplementary Fig. S3B). Meanwhile, they showed a decline in CD4<sup>+</sup> and CD8<sup>+</sup> T cells and  
282 natural killer (NK) cells at one month with a subsequent increase up to six months, which is  
283 consistent with the increased T cell responses observed by ELISpot between the three month and  
284 six month follow-ups (Fig. 5C). In addition, participants had higher CD19<sup>+</sup>CD27<sup>+</sup> memory B  
285 cells at three and six months compared to the other clusters (Supplementary Fig. S3B). The  
286 characteristics of the participants in this cluster were similar to those in the second cluster, but  
287 with only 8% requiring hospitalization during acute infection (Fig. 5D). Five of the participants  
288 in this cluster had another PCR-test between three and six months after their infection, none of  
289 which was positive. Together, cluster 3 appears to represent individuals with more mild disease  
290 and more moderate, less-well-sustained antibody responses. The increase in T cell responses  
291 between months three and six in these individuals may possibly represent a re-exposure event.

292         The *fourth cluster* (16% of the subsample) was characterized by the presence of  
293 antibodies and a rapid decline of T cells specific to all peptide pools between the two week and  
294 one month follow-up visits. By six months post-diagnosis, only 10% had detectable N-specific T  
295 cells and none had S2-specific T cells (Fig. 5C, Supplementary Fig. S3A). By flow cytometry,  
296 individuals in this cluster had higher total CD4<sup>+</sup> T cell numbers compared to clusters 2 and 3, but  
297 lower compared to clusters 1 and 5 at two weeks and one month, subsequently showing a decline  
298 in total CD4<sup>+</sup> and CD8<sup>+</sup> T cells up to six months post-diagnosis (Supplementary Fig. S3B). This  
299 cluster was characterized by participants who were predominantly male (80%), younger than 65

300 years (70%), and non- or ex-smokers (100%; Fig. 5D). About 40% reported having six  
301 symptoms or more and 40% were hospitalized in the acute phase. Together, cluster 4 appears to  
302 be comprised of young males with moderate to severe disease, but who also have less-well-  
303 sustained antibody and T cell responses.

304       The *fifth cluster* (39% of the subsample) was characterized by persistently low and  
305 primarily negative antibody responses and variable T cell responses. About half of the  
306 participants had detectable M- and N-specific T cells across all assessments. An increase in S1-  
307 and S2-specific T cells by three months was noted which was followed by a decline (Fig. 5C,  
308 Supplementary Fig. S3A). Despite T cells responses which tended to be lower than for other  
309 clusters by ELISpot, these individuals had higher total CD8<sup>+</sup> T cell numbers compared to all  
310 other clusters from one to six months post-diagnosis, as determined by flow cytometric analysis  
311 (Supplementary Fig. S3B). They also had high total CD4<sup>+</sup> T cell numbers compared to other  
312 clusters (though not as high as cluster 1 at two weeks to three months), and showed a steady  
313 increase in CD4<sup>+</sup> and CD8<sup>+</sup> T cells as well as NK cells up to six months (Supplementary Fig.  
314 S3B). Most individuals within this cluster were younger than 65 years (80%), female (68%), and  
315 had mild disease as reflected by the low reported symptom count with none of the individuals  
316 requiring hospitalization (Fig. 5D). That individuals in cluster 5 experience relatively mild  
317 disease in the absence of substantial antibody responses suggests compensatory protection by  
318 cell-mediated immune responses, possibly including T cells specific to viral proteins not  
319 captured by the assays used in this study.

320       Overall, our findings demonstrate the presence of different joint trajectories of antibody  
321 and T cell immune responses after SARS-CoV-2 infection, highlighting the large heterogeneity

322 between individuals. We found that within these clusters, individuals shared similar patterns of  
323 immune phenotypes as well as demographic and clinical characteristics.

324

325 **Demographic and clinical factors are associated with humoral and cellular immune**  
326 **responses**

327 We then evaluated whether the demographic and clinical factors described within the  
328 clusters were associated with antibody responses in the overall study population using adjusted  
329 mixed-effects linear regression analyses. Consistent with other reports (7, 17, 21, 27–30, 48), we  
330 found that older age ( $\geq 65$  years) ( $p < 0.001$ ), male sex ( $p = 0.011$ ), higher symptom severity  
331 defined as having one to five ( $p < 0.001$ ) or more than six COVID-19 symptoms ( $p < 0.001$ ), as  
332 well as hospitalization ( $p = 0.006$ ) were statistically significantly associated with higher anti-S-  
333 IgG MFI ratios over time (Fig. 6A, Supplementary Table S5). Conversely, being a current  
334 smoker was associated with lower responses ( $p = 0.010$ ). Results for anti-S-IgA MFI ratios in the  
335 overall population were comparable (Fig. 6B, Supplementary Table S5), and similar trends were  
336 identified for anti-N-IgG MFI ratios within the subsample (Fig. 6C). For T cell responses, we  
337 found that older age ( $\geq 65$  years) ( $p < 0.001$ ) and having more than six symptoms ( $p < 0.001$ ) during  
338 the acute infection were associated with higher T cell counts over time within the subsample  
339 (Fig. 6D, Supplementary Table S6). Sensitivity analyses for antibody or T cell positivity at two  
340 weeks and six months after diagnosis using logistic regression models showed comparable trends  
341 (Supplementary Tables S7 and S8). Therefore, severity of disease, age and smoking status are  
342 associated with the magnitude of immune responses.

343

## 344 **DISCUSSION**

345 Further understanding of the characteristics and trajectories of immune responses after  
346 natural infection remains important even with the rollout of vaccines worldwide. Here, we  
347 provide a longitudinal evaluation of humoral and cellular immune responses simultaneously,  
348 from shortly after, and up to 217 days after, SARS-CoV-2 infection, in a group of individuals  
349 infected between August 2020 and January 2021 and covering the full spectrum of clinical  
350 manifestation and S-specific antibody responses.

351

### 352 **Distinct kinetics of antibody and T cell responses by subset and specificity**

353 We demonstrate that approximately 85% of individuals infected with SARS-CoV-2  
354 develop S-specific IgA and IgG antibody responses, and that nearly all of these individuals  
355 maintain these responses for up to six months of follow-up. Compared to S-specific IgG,  
356 however, the proportion of participants with detectable anti-S-IgA decreased markedly over time  
357 (from 85% to 70% at six months). Consistent with this, we found the half-life of anti-S-IgA was  
358 considerably shorter (71 days, with a range of 42 to 210 days reported by other studies (2, 8, 18))  
359 compared to that of anti-S-IgG (145 days, with a range of 36 to 245 days reported by other  
360 studies (2, 8, 11, 33, 49–52)). This difference, however, is perhaps not surprising as the half-lives  
361 of IgA responses, in general, are shorter than those of IgG. Interestingly, we further found that  
362 anti-N-IgG responses waned more rapidly than those specific to S, with an estimated half-life of  
363 only 86 days. These findings are consistent with those from other studies demonstrating anti-S-  
364 IgG responses to be important for sustained protection against SARS-CoV-2. Furthermore, they  
365 indicate that both the target of the antibody response as well as the isotype itself appear to  
366 influence the duration of humoral immune responses after infection.



367 In the subsample of individuals selected to cover the full spectrum of clinical disease and  
368 S-specific antibody responses, we also found that the majority had detectable, IFN-gamma-  
369 producing T cell responses to at least one of the four peptide pools analyzed in this study. Based  
370 on this polyclonal T cell response, we estimate a half-life of 145 days, which is consistent with  
371 the literature (2, 8). Overall T cell positivity in the subsample (nearly 85%) was higher than for  
372 overall antibody seropositivity (just over 60%), suggesting that T cell responses are likely able to  
373 provide compensatory protection, even in the absence of antibodies. However, as only a limited  
374 range of antibody and T cell responses were tested here, it could also be possible that antibody  
375 responses to other viral proteins, or of other subtypes, are capable of providing this protection.

376 Furthermore, the T cell peptide pools for which individuals tested positive were  
377 heterogenous. For example, at six months, 50% of individuals were positive for any individual  
378 pool despite an overall T cell positivity of approximately 70%, which illustrates the polyclonal  
379 nature of the anti-viral T cell response. While M and S1 appeared to be immunodominant in  
380 terms of the magnitude of T cell responses, they also decayed more rapidly, with half-lives of  
381 128 and 126 days, compared to N and S2-specific responses with half-lives of 227 and 266 days,  
382 respectively. Compared to S1, the S2 domain of the full-length spike protein shares a higher  
383 degree of amino acid identity with endemic coronaviruses (53). For example, HCoV-HKU1  
384 shares an amino acid identity of 42% with SARS-CoV-2 at the S2 domain of the spike protein  
385 compared to 31% at the S1 domain. Therefore, the longer half-life of S2-specific, compared to  
386 S1-specific T cells, could potentially be due to intermittent exposure to endemic coronaviruses  
387 with similar S2 peptide sequences, resulting in the appearance of a prolonged and more durable  
388 T cell response. Overall, our findings suggest that M and S1 responses may initially be more

389 robust, at least in terms of an IFN-gamma-producing response, but that perhaps responses to N  
390 and S2 may be more durable.

391 In evaluating virus-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells by AIM assay we found that  
392 frequencies of AIM<sup>+</sup>CD4<sup>+</sup> or CD8<sup>+</sup> T cells were similar at two weeks post-infection, but that  
393 activated, virus-specific CD4<sup>+</sup> T cells tended to decline over the six months of follow-up,  
394 whereas levels of activated, virus-specific CD8<sup>+</sup> T cells remained more stable. Furthermore,  
395 CD4<sup>+</sup>AIM<sup>+</sup> T cells were predominantly of TCM phenotype, and this remained consistent  
396 throughout the convalescent period, whereas CD8<sup>+</sup>AIM<sup>+</sup> T cells had a predominantly TEMRA  
397 phenotype throughout this period consistent with previous studies (8, 54, 55). These findings  
398 support the idea that CD4<sup>+</sup> T cells may play an important role in maintaining the immune  
399 response and immunological memory, whereas CD8<sup>+</sup> T cells may play a more direct role in the  
400 anti-viral immune response as highly activated and more terminally-differentiated cytotoxic  
401 lymphocytes.

402

### 403 **Concordance of Antibody and T Cell Responses and Immune Response Trajectories**

404 We further evaluated the relationship between antibody and T cell responses within  
405 individuals over time, as well as the patterns of these responses within the population. We found  
406 a strong, positive correlation between the three antibody subtypes evaluated here. Similarly, T  
407 cell responses to M, N, S1, and S2 peptide pools also demonstrated a strong positive correlation,  
408 suggesting that, although there may be some variation between distinct subtypes or specificities,  
409 both overall antibody and T cell responses tended to behave similarly.

410           The relationship between antibody and T cell responses, however, was less strong. We  
411 observed a weak to moderate positive correlation early after infection, where increased antibody  
412 responses tended to predict increased T cell responses to some degree. Meanwhile, correlations  
413 became weaker later during follow-up and were weak or no longer present by six months. In  
414 assessing the concordance between antibody and T cell responses, we also found that, at two  
415 weeks, more than 70% of participants had concordant results (58% both antibody and T cell  
416 positive and 13% both antibody and T cell negative). After six months, this dropped to 55-60%.  
417 These findings suggest that individuals had differing immune responses following infection  
418 (possibly due to differences in viral load or primary site of infection or previous immune  
419 history), and that they perhaps retain differing subsets of immune memory components which  
420 could be recalled upon reinfection.

421           Based on this idea, we explored whether there are heterogeneous immune trajectories  
422 which individuals tend to follow in response to infection, and which might influence not only  
423 their response to infection, but also the immune memory populations which they establish. Using  
424 a longitudinal clustering algorithm, we assessed different patterns of immune responses between  
425 individuals over time. We identified five distinct joint trajectories of antibody and T cell  
426 responses. These trajectories were primarily based on the presence or absence of antibodies and  
427 varying T cell responses. Interestingly, we observed distinct clinical characteristics between  
428 these clusters. We found that clusters with the most robust immune responses, i.e., clusters 1 and  
429 2, included older participants who had more severe COVID-19 as reflected by hospitalization  
430 and the number of reported symptoms. This finding is not surprising as older age and disease  
431 severity have been consistently reported to be associated with higher immune responses to  
432 SARS-CoV-2 (7, 17, 21, 27–30), and other studies primarily conducted in patients with severe

433 COVID-19 or requiring hospitalization observed similar patterns (4, 16, 21). These findings were  
434 confirmed in association analyses in the overall study population, in which we found that older  
435 age, male sex, and higher disease severity were strongly associated with stronger immune  
436 responses. In contrast, clusters 4 and 5 appeared to have less robust antibody and T cell  
437 responses. Cluster 5, in which participants were distinctly antibody negative, consisted mainly of  
438 younger females who reported mild COVID-19 or asymptomatic infection. Some T cell  
439 responses were present in half of these participants which, in conjunction with the generally less  
440 severe presentation, may point towards compensatory mechanisms of T cell populations in  
441 protecting from more severe COVID-19. Remarkably, in cluster 3, we noted a considerable  
442 increase in virus-specific T cells, and, to a lesser extent, in anti-S-IgA, after an initial decline up  
443 to three months after infection. In combination with the increase in N-specific T cells, this may  
444 indicate a possible re-exposure to the virus. Of note, about half of cluster participants underwent  
445 SARS-CoV-2 testing between three and six months, which may be indicative of potential  
446 exposure events or symptomatic episodes. None, however, tested positive. This again highlights  
447 the role of the immune system in protecting from severe disease upon re-exposure, as  
448 reinfections may present with milder disease than the primary infection or may even be  
449 asymptomatic. Furthermore, this finding demonstrates that reinfections might be more frequent  
450 than reported, since many would remain undetected.

451

## 452 **Limitations**

453 Our cohort is one of few population-based and longitudinal studies assessing various  
454 components of the immune system in a sample of patients that is representative of the full  
455 spectrum of COVID-19. However, some limitations should be considered when interpreting our

456 findings. We used single assays to measure antibodies or T cells in our study. The accuracy and  
457 detection levels may differ between tests and thus individuals who are negative in one assay may  
458 not be so in another. Nevertheless, the Luminex assay that we used for antibody detection has  
459 been extensively validated and was shown to be highly sensitive and specific (45). Second, we  
460 did not measure the neutralizing capacity of antibody responses. However, other studies have  
461 shown that neutralizing capacity correlates strongly with measured levels of binding antibodies  
462 (3, 25, 56). Third, we limited our T cell analysis to the three dominant antigens for cellular  
463 immune responses (S, M and N) (2, 8, 57). However, we cannot exclude that in some of the  
464 participants, subdominant T cell responses against other viral antigens play important roles,  
465 which may have led to an underestimation of the proportion of individuals with T cell responses.  
466 Fourth, the cluster analysis bears the limitations that are inherent to the methodology. Using a  
467 clustering algorithm that separates the study population into distinct clusters may not be  
468 necessarily reflective of clinically meaningful differences. However, we identified distinct  
469 clinical and immunological correlates within the different clusters, including various factors  
470 (such as the data from flow cytometry) that were not used within the clustering model.  
471 Therefore, we consider our results to be relatively robust and leading to a meaningful description  
472 of different immune trajectories. Finally, we analyzed antibody and T cell testing results only up  
473 to six months, limiting our findings regarding the durability of immune responses. Furthermore,  
474 the limited sample size was a pragmatic choice to ensure feasibility of the project, and further  
475 immune response patterns may have been observable with additional data. Nonetheless, we  
476 believe our study provides a valuable and unique in-depth analysis of joint humoral and cellular  
477 immune response trajectories which may lead to further insights on the variability of immune  
478 responses to SARS-CoV-2.

479

## 480 **Conclusion**

481           In conclusion, our analyses provide important insights into the different dynamics of  
482 antibody and T cell immune responses in individuals covering the entire range from  
483 asymptomatic to severe courses of COVID-19. Based on the observed humoral and cellular  
484 immune responses, we identify variable immunological trajectories and categorize these into five  
485 distinct clusters. While antibody and T cell responses strongly correlate in some individuals,  
486 their discordance in other individuals may point towards more complex interactions of the  
487 immune system among infected individuals. Overall, our findings indicate that virus-specific T  
488 cell responses may be compensatory in the absence of humoral immunity against SARS-CoV-2.

489

## 490 **MATERIALS AND METHODS**

### 491 **Study Design and Participants**

492           We recruited a population-based, age-stratified, random sample of 431 individuals  
493 diagnosed with SARS-CoV-2 infection between 6 August 2020 and 19 January 2021 in the  
494 Canton of Zurich, Switzerland. Study participants were identified through the Department of  
495 Health of the Canton of Zurich, which records all diagnosed SARS-CoV-2 cases within the  
496 Canton through mandatory case reporting. Eligibility criteria were having a polymerase chain  
497 reaction (PCR)-confirmed SARS-CoV-2 diagnosis, being aged 18 years or older, residing in the  
498 Canton of Zurich, understanding the German language, and being cognitively able to follow the  
499 study procedures. We obtained written informed consent from all participants upon study

500 enrollment. The study protocol was approved by the Cantonal Ethics Committee of Zurich  
501 (BASEC Registration No. 2020-01739) and prospectively registered (ISRCTN 14990068) (58).

502 We collected peripheral venous blood samples during study visits at two weeks, one  
503 month, three months and six months post-diagnosis. Participants additionally provided  
504 information regarding acute COVID-19 disease course, severity and symptoms, longer-term  
505 health and complications, past medical history, and socio-demographics at the corresponding  
506 timepoints through electronic questionnaires.

507 We selected 64 out of the 431 participants for a detailed characterization of immune  
508 responses. This sample was aimed to be representative of the full spectrum of SARS-CoV-2  
509 infection and associated immune responses. Participants in this subsample were selected at  
510 random within strata based on clinical characteristics (asymptomatic disease, low and high  
511 symptom count, hospitalization) and antibody responses up to one month (negative or low anti-  
512 S-IgA or -IgG response, positive or high anti-S-IgA or -IgG response), while ensuring balance  
513 across sex and age groups. Based on preliminary assessments and evidence from other studies,  
514 we deemed this sample size to be a sensible and pragmatic choice allowing to identify the range  
515 and distinct trajectories of immune responses in infected individuals, while ensuring the  
516 feasibility of the project.

517

## 518 **Isolation of Plasma and PBMCs**

519 K2 EDTA blood samples collected from participants at each study timepoint were  
520 subjected to initial centrifugation to collect plasma, followed by isolation of PBMCs from the  
521 remaining cellular fraction by density-gradient centrifugation using Ficoll–Paque (density

522 1.077g/ml). Plasma aliquots were stored at -20°C prior to IgA and IgG antibody titer analyses.  
523 PBMCs were initially frozen at -80°C and transferred to liquid nitrogen prior to use in ELISpot  
524 and Activation Induced Marker (AIM) Flow Cytometry assays.

525

## 526 **Analysis of Spike-Specific IgA and IgG and Nucleocapsid-Specific IgG**

527 Frozen plasma samples were thawed and analyzed for levels of Spike (S)-specific IgA  
528 and IgG, or Nucleocapsid (N)-specific IgG by Luminex assay as described elsewhere (45). In  
529 brief, assay beads were prepared by covalent coupling of either the SARS-CoV-2 Spike protein  
530 trimer, or N-protein, with MagPlex beads using a Bio-Plex 356 Amine Coupling Kit (Bio-Rad)  
531 per manufacturer's protocol. Protein-coupled beads were diluted and added to each well of Bio-  
532 Plex Pro 96-well Flat Bottom Plates (Bio-Rad). Beads were washed with PBS on a magnetic  
533 plate washer (MAG2x program) and 50ul of individual serum samples diluted 1:300 in PBS were  
534 added to plate wells. A pool of pre-Covid-19 pandemic healthy human sera was used as a  
535 negative control (BioWest human serum AB males; VWR). Plates were incubated for 1 hour at  
536 room temperature with shaking, washed with PBS and incubated with 50ul of a 1:100 dilution of  
537 anti-human IgA-PE (for anti-IgA assay) or IgG-PE (for anti-IgG assay) secondary antibody  
538 (OneLambda ThermoFisher) at room temperature for an additional 45 minutes with shaking.  
539 After incubation, samples were washed with PBS and resuspended in reading buffer and read on  
540 a Luminex FLEXMAP 3D plate reader (ThermoFisher) to obtain a Mean Fluorescence Intensity  
541 (MFI) value for each sample. The MFI value for each serum sample was divided by the mean  
542 value of the negative control samples to yield an MFI ratio. Based on negative control samples  
543 and samples from PCR-positive donors, cut-off thresholds for MFI ratios used to determine  
544 seropositivity were 6.5 for IgA and 6.0 for IgG. The lower limit of measured MFI ratios was



545 restricted to 1, representing equivalent fluorescence intensity compared to negative control  
546 samples. For anti-S-IgG MFI ratios, an approximate conversion to BAU/ml is available based on  
547 a cross-validation with the Roche Elecsys Anti-SARS-CoV-2 S immunoassay, for which a  
548 reference table is provided (Supplementary Table S9).

549

## 550 **ELISpot Assay**

551 T cell responses were assessed by ELISpot assay using the Human IFN-gamma ELISpot  
552 Assay kit (R&D Systems) following the manufacturer's instructions. For the assay,  
553 cryopreserved PBMCs were thawed and plated at 5e5 cells per well. Cells were stimulated 20h at  
554 37°C with overlapping 15mer peptide pools spanning the entire M and N proteins or the S1  
555 domain of the spike protein or a mix of the predicted immunodominant peptides from the spike  
556 protein containing the majority of the S2 domain (M, N, S1 and S PepTivator peptide pools,  
557 respectively; Miltenyi Biotec) at a concentration of 1ug/ml per individual peptide. As negative  
558 controls, cells were incubated without peptide. As positive controls, 2.5e5 cells per well were  
559 stimulated with anti-CD3 antibody (OKT3; Miltenyi Biotec). Spots were counted using an AID  
560 iSpot Reader System with EliSpot 7.0 software (AID). Two times the number of spots in  
561 unstimulated negative control wells were subtracted from the values of each test well and results  
562 were normalized to the number of spots in anti-CD3 antibody-stimulated wells from the same  
563 individual and timepoint and presented as spot-forming units (SFU) per 1e6 CD3+ cells. Results  
564 were excluded if positive control wells were negative.

565

## 566 **Flow Cytometry and Activation-Induced Marker (AIM) Assay**

567 Cryopreserved PBMCs were thawed in RPMI-1640 (Gibco, Thermo Fisher Scientific)  
568 supplemented with 5% human AB-serum (BioConcept) and 25U/ml benzonase (Sigma), and  
569 plated in 96-UWell plates (Sarstedt) at a concentration of up to 1e6 cells per well in RPMI-1640  
570 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% human AB-serum  
571 (BioConcept) and 1% Penicillin-Streptomycin (Thermo Fisher). SARS-CoV-2 PepTivator  
572 peptide pools M, N, S1 and S (Miltenyi Biotec) were dissolved per manufacturer's instructions in  
573 sterile water and combined into a single mega pool. PBMCs were cultured for 24h in a  
574 humidified incubator at 37°C and 5% CO<sub>2</sub> in the presence of either the SARS-CoV-2 mega pool  
575 at 0.6nmol (appr. 1µg) of each peptide/ml, Phytohemagglutinin-L at 5µg/ml (Merck Millipore,  
576 positive control) or culture medium (unstimulated condition). Peptide- and unstimulated samples  
577 were run in duplicate whenever possible and longitudinal samples from individual participants  
578 were included in the same assay. After 24 hours, cells were washed in staining buffer (PBS,  
579 0.02% NaN<sub>3</sub>, 2mM EDTA, 1% bovine serum albumin), blocked for 10 minutes with Human  
580 TruStain FcX (Biolegend) on ice and stained for 30 minutes at 4°C with the following antibodies  
581 in buffer supplemented with Super Bright Complete Staining Buffer (eBioscience): BUV395  
582 anti-CD45RA (Clone: HI100, BD Bioscience, RRID:AB\_2740037), BUV496 anti-CD8 (Clone:  
583 RPA-T8, BD Bioscience, RRID:AB\_2870223), BUV563 anti-CD56 (Clone: NCAM16.2, BD  
584 Bioscience, RRID:AB\_2870213), BUV661 anti-CD14 (Clone: M5E2, BD Bioscience,  
585 RRID:AB\_2871011), BUV737 anti-CD16 (Clone: 3G8, BD Bioscience, RRID:AB\_2869578),  
586 BUV805 anti-CD19 (Clone: SJ25C1, BD Bioscience, RRID:AB\_2873553), BV421 anti-CD27  
587 (Clone: O323, Biolegend, RRID:AB\_11150782), BV510 anti-CD4 (Clone: OKt4, Biolegend,  
588 RRID:AB\_2561866), BV650 anti-CD38 (Clone: HB-7, Biolegend, RRID:AB\_2566233), BV786  
589 anti-CD3 (Clone: OKt3, Biolegend, RRID:AB\_2563507), PE anti-IgD (Clone: IA6-2, Biolegend,

590 RRID:AB\_10553900), PE/Dazzle594 anti-CCR7 (Clone: G043H7, Biolegend,  
591 RRID:AB\_2563641), FITC anti-HLA-DR (Clone: L243, Biolegend, RRID:AB\_314682), PE-  
592 Cy7 anti-CD137 (Clone: 4B4-1, Biolegend, RRID:AB\_2207741), BB700 anti-CD134/OX40  
593 (Clone: ACT35, BD Bioscience, RRID:AB\_2743451), APC anti-CD69 (Clone: FN50,  
594 Biolegend, RRID:AB\_314845). Zombie NIR Fixable Viability Dye (Biolegend) was used to  
595 exclude dead cells. After washing, samples were fixed with 1% PFA and acquired on Cytex  
596 Aurora 5L spectral flow cytometer (Cytex). Data was analyzed using Cytex SpectroFlo (version  
597 3.0.1) and FlowJo software (version 10, TreeStar Inc). Samples were excluded if the percentage  
598 of live leukocytes was below 25%. SARS-CoV-2 antigen-specific T cells were measured as  
599 AIM<sup>+</sup> (CD134<sup>+</sup>CD137<sup>+</sup>) CD4<sup>+</sup> T and (CD69<sup>+</sup>CD137<sup>+</sup>) CD8<sup>+</sup> T cells. Unspecific activation in  
600 unstimulated controls was subtracted and negative values were set to zero.

601

## 602 **Statistical Analyses**

603 We summarized population characteristics descriptively and report frequencies and  
604 percentage or median and interquartile range, as applicable. We report age-stratified summary  
605 statistics for the frequency of antibody and T cell responses and calculated 95% Wilson  
606 confidence intervals to estimate the associated uncertainty. We excluded any data measured after  
607 receipt of COVID-19 vaccination (first dose; n=2 participants at three months and n=78  
608 participants at six months) or diagnosed reinfection (based on self-reported positive PCR or rapid  
609 antigen test; n=3 participants at six months) from all analyses. All data were transformed using  
610 natural logarithms for all comparative and associational analyses due to non-normal distributions  
611 and ratio properties of the Ig MFI ratios (zero values being replaced by half of the lowest non-  
612 zero value). Results are visualized using a log<sub>10</sub>-transformation in figures.

613 To estimate antibody decay times, we first determined the maximum response timepoint  
614 for each individual. We excluded data from individuals that were never tested positive for the  
615 respective antibody (i.e., anti-S-IgA or -IgG, or anti-N-IgG). We then restricted the data to the  
616 maximum and all subsequent timepoints and rescaled the time axis to start with the maximum  
617 concentration, in order to restrict and align the data for the descending slope of antibody decay  
618 (in line with previous studies (59, 60)). For T cells, we used the data as measured, as peak T cell  
619 expansion typically occurs in the first week after infection (61). We then fitted uni- and  
620 multivariable mixed-effects linear decay models on the natural logarithm-transformed data using  
621 random intercepts for individuals. We then calculated the half-life in days using the formula  $\lambda =$   
622  $\ln(0.5) / \beta$ , where  $\beta$  is the model-derived intercept (and associated uncertainty bounds). We  
623 used mixed-model-based parametric bootstrap for the visualization of confidence bounds.

624 For assessing the correlation of antibody and T cell test results, we calculated Spearman  
625 correlation coefficients for all combinations of antibody subtypes and epitope-specific T cells.  
626 Furthermore, we assessed concordance by calculating the proportion of participants testing  
627 positive or negative for antibody subtypes and overall T cells. And last, we further assessed  
628 agreement by calculating unweighted Cohen's Kappa values for test positivity for all possible  
629 combinations of antibody subtypes and virus-specific T cells.

630 We assessed the association between demographic and clinical factors and IgA and IgG  
631 MFI ratios up to six months after diagnosis using uni- and multivariable mixed-effects linear  
632 regression models. Model selection was based on prior knowledge and the Akaike and Bayesian  
633 Information Criteria (AIC/BIC), with a difference of 2 points considered relevant. Age, sex, and  
634 time since diagnosis were defined as a priori variables based on findings from previous studies.

635 We conducted sensitivity analyses for antibody positivity at two weeks and six months after  
636 diagnosis using uni- and multivariable logistic regression analyses.

637 To identify clusters of individuals with similar immune response trajectories over the four  
638 assessment timepoints, we used the *KmL3D* *k*-means clustering method which allows the joint  
639 evolution of multiple variables with repeated measures (46, 47). The algorithm requires  
640 predefining the number of clusters. We chose four to six clusters based on a priori knowledge on  
641 immune response patterns as well as exploratory analyses of the data. We specified 100 runs for  
642 each *k* clusters (i.e., 300 times in total) and specified Euclidean distance with Gower adjustment  
643 to estimate similarity between the trajectories. The selection of the final number of clusters was  
644 based on maximizing the Calinski and Harabatz quality criterion (46, 47) as well as the expected  
645 patterns in the data. Implementing the *KmL3D* algorithm requires that data for all variables  
646 included in the analysis are available for all participants. Hence, missing data were imputed by  
647 applying linear extrapolation with added variation (“Copy Mean” function (46, 47)). We plotted  
648 the mean antibody and T cell responses for each cluster to explore differences in respective  
649 immune response trajectories. Finally, we descriptively compared demographic and clinical  
650 features of individuals in clusters to identify specific factors associated with each trajectory.

651 All analyses were performed using *R* (v4.1.1) (62), using the *Hmisc* (v4.5-0), *lme4* (v1.1-  
652 27.1), *lmerTest* (v3.1-3) and *KmL3D* (v2.4.2) packages, and results were visualized using the  
653 *ggplot2* (v3.3.5), *ggpubr* (v0.4.0) and *pheatmap* (v1.0.12) packages.

654

655 **Supplementary Materials**

656 Fig. S1. Overall antibody and T cell positivity across timepoints and estimation of T cell decay  
657 kinetics.

658 Fig. S2. Concordance of antibody and T cell positivity over time.

659 Fig. S3. Antibody responses, cellular subsets and AIM+ T cells within clusters.

660 Table S1. Study population characteristics.

661 Table S2. Anti-S-IgA and -IgG antibody responses in the overall study population over time.

662 Table S3. Antibody and T cell responses in the subsample over time.

663 Table S4. Sensitivity analysis regarding anti-S-IgA and -IgG antibody responses, weighted by  
664 age group.

665 Table S5. Association between demographic and clinical factors and antibody responses over  
666 time.

667 Table S6. Association between demographic and clinical factors and T cell responses over time.

668 Table S7. Association between demographic and clinical factors and anti-S-IgG antibody  
669 positivity at two weeks and six months.

670 Table S8. Association between demographic and clinical factors and overall T cell positivity at  
671 two weeks and six months.

672 Table S9. Reference table for converting anti-S-IgG MFI ratios to BAU/ml (based on Roche  
673 Elecsys Anti-SARS-CoV-2 S immunoassay).

674

## 675 **References and Notes**

- 676 1. COVID Live Update: 259,111,945 Cases and 5,184,802 Deaths from the Coronavirus -  
677 Worldometer, (available at <https://www.worldometers.info/coronavirus/>).
- 678 2. A. K. Wheatley, J. A. Juno, J. J. Wang, K. J. Selva, A. Reynaldi, H.-X. Tan, W. S. Lee, K.  
679 M. Wragg, H. G. Kelly, R. Esterbauer, S. K. Davis, H. E. Kent, F. L. Mordant, T. E.  
680 Schlub, D. L. Gordon, D. S. Khoury, K. Subbarao, D. Cromer, T. P. Gordon, A. W. Chung,  
681 M. P. Davenport, S. J. Kent, Evolution of immune responses to SARS-CoV-2 in mild-  
682 moderate COVID-19. *Nat Commun.* **12**, 1162 (2021).
- 683 3. W. N. Chia, F. Zhu, S. W. X. Ong, B. E. Young, S.-W. Fong, N. L. Bert, C. W. Tan, C. Tiu,  
684 J. Zhang, S. Y. Tan, S. Pada, Y.-H. Chan, C. Y. L. Tham, K. Kunasegaran, M. I.-C. Chen,  
685 J. G. H. Low, Y.-S. Leo, L. Renia, A. Bertoletti, L. F. P. Ng, D. C. Lye, L.-F. Wang,  
686 Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a  
687 longitudinal study. *The Lancet Microbe.* **2**, e240–e249 (2021).
- 688 4. K. Li, B. Huang, M. Wu, A. Zhong, L. Li, Y. Cai, Z. Wang, L. Wu, M. Zhu, J. Li, Z. Wang,  
689 W. Wu, W. Li, B. Bosco, Z. Gan, Q. Qiao, J. Wu, Q. Wang, S. Wang, X. Xia, Dynamic  
690 changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from  
691 COVID-19. *Nature Communications.* **11**, 6044 (2020).
- 692 5. K. Wang, Q.-X. Long, H.-J. Deng, J. Hu, Q.-Z. Gao, G.-J. Zhang, C.-L. He, L.-Y. Huang,  
693 J.-L. Hu, J. Chen, N. Tang, A.-L. Huang, Longitudinal Dynamics of the Neutralizing  
694 Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  
695 Infection. *Clin Infect Dis.* **73**, e531–e539 (2021).

- 696 6. K. K.-W. To, O. T.-Y. Tsang, W.-S. Leung, A. R. Tam, T.-C. Wu, D. C. Lung, C. C.-Y.  
697 Yip, J.-P. Cai, J. M.-C. Chan, T. S.-H. Chik, D. P.-L. Lau, C. Y.-C. Choi, L.-L. Chen, W.-  
698 M. Chan, K.-H. Chan, J. D. Ip, A. C.-K. Ng, R. W.-S. Poon, C.-T. Luo, V. C.-C. Cheng, J.  
699 F.-W. Chan, I. F.-N. Hung, Z. Chen, H. Chen, K.-Y. Yuen, Temporal profiles of viral load  
700 in posterior oropharyngeal saliva samples and serum antibody responses during infection by  
701 SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*. **20**, 565–574  
702 (2020).
- 703 7. K. L. Lynch, J. D. Whitman, N. P. Lacanienta, E. W. Beckerdite, S. A. Kastner, B. R. Shy,  
704 G. M. Goldgof, A. G. Levine, S. P. Bapat, S. L. Stramer, J. H. Esensten, A. W. Hightower,  
705 C. Bern, A. H. B. Wu, Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and  
706 their relationship to disease severity. *Clin Infect Dis*, ciaa979 (2020).
- 707 8. J. M. Dan, J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, A. Grifoni, S. I.  
708 Ramirez, S. Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S. A. Rawlings, B. Peters, F.  
709 Krammer, V. Simon, E. O. Saphire, D. M. Smith, D. Weiskopf, A. Sette, S. Crotty,  
710 Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.  
711 *Science*. **371**, eabf4063 (2021).
- 712 9. A. Grifoni, D. Weiskopf, S. I. Ramirez, J. Mateus, J. M. Dan, C. R. Moderbacher, S. A.  
713 Rawlings, A. Sutherland, L. Premkumar, R. S. Jadi, D. Marrama, A. M. de Silva, A.  
714 Frazier, A. F. Carlin, J. A. Greenbaum, B. Peters, F. Krammer, D. M. Smith, S. Crotty, A.  
715 Sette, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-  
716 19 Disease and Unexposed Individuals. *Cell*. **181**, 1489-1501.e15 (2020).
- 717 10. L. B. Rodda, J. Netland, L. Shehata, K. B. Pruner, P. A. Morawski, C. D. Thouvenel, K. K.  
718 Takehara, J. Eggenberger, E. A. Hemann, H. R. Waterman, M. L. Fahning, Y. Chen, M.



- 719 Hale, J. Rathe, C. Stokes, S. Wrenn, B. Fiala, L. Carter, J. A. Hamerman, N. P. King, M.  
720 Gale, D. J. Campbell, D. J. Rawlings, M. Pepper, Functional SARS-CoV-2-Specific  
721 Immune Memory Persists after Mild COVID-19. *Cell*. **184**, 169-183.e17 (2021).
- 722 11. D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K.  
723 Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are  
724 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat*  
725 *Med*. **27**, 1205–1211 (2021).
- 726 12. L. Ni, F. Ye, M.-L. Cheng, Y. Feng, Y.-Q. Deng, H. Zhao, P. Wei, J. Ge, M. Gou, X. Li, L.  
727 Sun, T. Cao, P. Wang, C. Zhou, R. Zhang, P. Liang, H. Guo, X. Wang, C.-F. Qin, F. Chen,  
728 C. Dong, Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-  
729 19 Convalescent Individuals. *Immunity*. **52**, 971-977.e3 (2020).
- 730 13. Y. Chen, A. Zuiani, S. Fischinger, J. Mullur, C. Atyeo, M. Travers, F. J. N. Lelis, K. M.  
731 Pullen, H. Martin, P. Tong, A. Gautam, S. Habibi, J. Bensko, D. Gakpo, J. Feldman, B. M.  
732 Hauser, T. M. Caradonna, Y. Cai, J. S. Burke, J. Lin, J. A. Lederer, E. C. Lam, C. L.  
733 Lavine, M. S. Seaman, B. Chen, A. G. Schmidt, A. B. Balazs, D. A. Lauffenburger, G.  
734 Alter, D. R. Wesemann, Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody  
735 Production. *Cell*. **183**, 1496-1507.e16 (2020).
- 736 14. S. Fafi-Kremer, T. Bruel, Y. Madec, R. Grant, L. Tondeur, L. Grzelak, I. Staropoli, F.  
737 Anna, P. Souque, S. Fernandes-Pellerin, N. Jolly, C. Renaudat, M.-N. Ungeheuer, C.  
738 Schmidt-Mutter, N. Collongues, A. Bolle, A. Velay, N. Lefebvre, M. Mielcarek, N. Meyer,  
739 D. Rey, P. Charneau, B. Hoen, J. D. Seze, O. Schwartz, A. Fontanet, Serologic responses to  
740 SARS-CoV-2 infection among hospital staff with mild disease in eastern France.  
741 *EBioMedicine*. **59** (2020), doi:10.1016/j.ebiom.2020.102915.

- 742 15. Q.-X. Long, B.-Z. Liu, H.-J. Deng, G.-C. Wu, K. Deng, Y.-K. Chen, P. Liao, J.-F. Qiu, Y.  
743 Lin, X.-F. Cai, D.-Q. Wang, Y. Hu, J.-H. Ren, N. Tang, Y.-Y. Xu, L.-H. Yu, Z. Mo, F.  
744 Gong, X.-L. Zhang, W.-G. Tian, L. Hu, X.-X. Zhang, J.-L. Xiang, H.-X. Du, H.-W. Liu, C.-  
745 H. Lang, X.-H. Luo, S.-B. Wu, X.-P. Cui, Z. Zhou, M.-M. Zhu, J. Wang, C.-J. Xue, X.-F.  
746 Li, L. Wang, Z.-J. Li, K. Wang, C.-C. Niu, Q.-J. Yang, X.-J. Tang, Y. Zhang, X.-M. Liu, J.-  
747 J. Li, D.-C. Zhang, F. Zhang, P. Liu, J. Yuan, Q. Li, J.-L. Hu, J. Chen, A.-L. Huang,  
748 Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med.* **26**, 845–848  
749 (2020).
- 750 16. J. Zhao, Q. Yuan, H. Wang, W. Liu, X. Liao, Y. Su, X. Wang, J. Yuan, T. Li, J. Li, S. Qian,  
751 C. Hong, F. Wang, Y. Liu, Z. Wang, Q. He, Z. Li, B. He, T. Zhang, Y. Fu, S. Ge, L. Liu, J.  
752 Zhang, N. Xia, Z. Zhang, Antibody Responses to SARS-CoV-2 in Patients With Novel  
753 Coronavirus Disease 2019. *Clin Infect Dis.* **71**, 2027–2034 (2020).
- 754 17. D. F. Gudbjartsson, G. L. Norddahl, P. Melsted, K. Gunnarsdottir, H. Holm, E. Eythorsson,  
755 A. O. Arnthorsson, D. Helgason, K. Bjarnadottir, R. F. Ingvarsson, B. Thorsteinsdottir, S.  
756 Kristjansdottir, K. Birgisdottir, A. M. Kristinsdottir, M. I. Sigurdsson, G. A. Arnadottir, E.  
757 V. Ivarsdottir, M. Andresdottir, F. Jonsson, A. B. Agustsdottir, J. Berglund, B. Eiriksdottir,  
758 R. Fridriksdottir, E. E. Gardarsdottir, M. Gottfredsson, O. S. Gretarsdottir, S.  
759 Gudmundsdottir, K. R. Gudmundsson, T. R. Gunnarsdottir, A. Gylfason, A. Helgason, B.  
760 O. Jensson, A. Jonasdottir, H. Jonsson, T. Kristjansson, K. G. Kristinsson, D. N.  
761 Magnusdottir, O. T. Magnusson, L. B. Olafsdottir, S. Rognvaldsson, L. le Roux, G.  
762 Sigmundsdottir, A. Sigurdsson, G. Sveinbjornsson, K. E. Sveinsdottir, M. Sveinsdottir, E.  
763 A. Thorarensen, B. Thorbjornsson, M. Thordardottir, J. Saemundsdottir, S. H. Kristjansson,  
764 K. S. Josefsdottir, G. Masson, G. Georgsson, M. Kristjansson, A. Moller, R. Palsson, T.

- 765 Gudnason, U. Thorsteinsdottir, I. Jonsdottir, P. Sulem, K. Stefansson, Humoral Immune  
766 Response to SARS-CoV-2 in Iceland. *New England Journal of Medicine*. **383**, 1724–1734  
767 (2020).
- 768 18. A. S. Iyer, F. K. Jones, A. Nodoushani, M. Kelly, M. Becker, D. Slater, R. Mills, E. Teng,  
769 M. Kamruzzaman, W. F. Garcia-Beltran, M. Astudillo, D. Yang, T. E. Miller, E. Oliver, S.  
770 Fischinger, C. Atyeo, A. J. Iafrate, S. B. Calderwood, S. A. Lauer, J. Yu, Z. Li, J. Feldman,  
771 B. M. Hauser, T. M. Caradonna, J. A. Branda, S. E. Turbett, R. C. LaRocque, G. Mellon, D.  
772 H. Barouch, A. G. Schmidt, A. S. Azman, G. Alter, E. T. Ryan, J. B. Harris, R. C. Charles,  
773 Persistence and decay of human antibody responses to the receptor binding domain of  
774 SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol*. **5**, eabe0367 (2020).
- 775 19. J. Prévost, R. Gasser, G. Beaudoin-Bussi eres, J. Richard, R. Duerr, A. Laumaea, S. P.  
776 Anand, G. Goyette, M. Benlarbi, S. Ding, H. Medjahed, A. Lewin, J. Perreault, T.  
777 Tremblay, G. Gendron-Lepage, N. Gauthier, M. Carrier, D. Marcoux, A. Pich e, M. Lavoie,  
778 A. Benoit, V. Loungnarath, G. Brochu, E. Haddad, H. D. Stacey, M. S. Miller, M.  
779 Desforges, P. J. Talbot, G. T. G. Maule, M. C ot e, C. Therrien, B. Serhir, R. Bazin, M.  
780 Roger, A. Finzi, Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2  
781 Spike. *Cell Rep Med*. **1**, 100126 (2020).
- 782 20. H. Hou, T. Wang, B. Zhang, Y. Luo, L. Mao, F. Wang, S. Wu, Z. Sun, Detection of IgM  
783 and IgG antibodies in patients with coronavirus disease 2019. *Clin Transl Immunology*. **9**,  
784 e1136 (2020).
- 785 21. B. Zhang, X. Zhou, C. Zhu, Y. Song, F. Feng, Y. Qiu, J. Feng, Q. Jia, Q. Song, B. Zhu, J.  
786 Wang, Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level

- 787 Predicts Disease Severity and Outcome for Patients With COVID-19. *Frontiers in*  
788 *Molecular Biosciences*. **7**, 157 (2020).
- 789 22. M. S. Suthar, M. G. Zimmerman, R. C. Kauffman, G. Mantus, S. L. Linderman, W. H.  
790 Hudson, A. Vanderheiden, L. Nyhoff, C. W. Davis, O. Adekunle, M. Affer, M. Sherman, S.  
791 Reynolds, H. P. Verkerke, D. N. Alter, J. Guarner, J. Bryksin, M. C. Horwath, C. M.  
792 Arthur, N. Saakadze, G. H. Smith, S. Edupuganti, E. M. Scherer, K. Hellmeister, A. Cheng,  
793 J. A. Morales, A. S. Neish, S. R. Stowell, F. Frank, E. Ortlund, E. J. Anderson, V. D.  
794 Menachery, N. Roupael, A. K. Mehta, D. S. Stephens, R. Ahmed, J. D. Roback, J.  
795 Wrammert, Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.  
796 *Cell Reports Medicine*. **1**, 100040 (2020).
- 797 23. P. J. M. Brouwer, T. G. Caniels, K. van der Straten, J. L. Snitselaar, Y. Aldon, S. Bangaru,  
798 J. L. Torres, N. M. A. Okba, M. Claireaux, G. Kerster, A. E. H. Bentlage, M. M. van  
799 Haaren, D. Guerra, J. A. Burger, E. E. Schermer, K. D. Verheul, N. van der Velde, A. van  
800 der Kooi, J. van Schooten, M. J. van Breemen, T. P. L. Bijl, K. Sliepen, A. Aartse, R.  
801 Derking, I. Bontjer, N. A. Kootstra, W. J. Wiersinga, G. Vidarsson, B. L. Haagmans, A. B.  
802 Ward, G. J. de Bree, R. W. Sanders, M. J. van Gils, Potent neutralizing antibodies from  
803 COVID-19 patients define multiple targets of vulnerability. *Science*. **369**, 643–650 (2020).
- 804 24. T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W. He, O. Limbo, C. Smith, G.  
805 Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L.  
806 Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M.  
807 Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E.  
808 Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing

- 809 antibodies and protection from disease in a small animal model. *Science*. **369**, 956–963  
810 (2020).
- 811 25. A. Wajnberg, F. Amanat, A. Firpo, D. R. Altman, M. J. Bailey, M. Mansour, M. McMahon,  
812 P. Meade, D. R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, S. Strohmeier, V. Simon, J.  
813 Aberg, D. L. Reich, F. Krammer, C. Cordon-Cardo, Robust neutralizing antibodies to  
814 SARS-CoV-2 infection persist for months. *Science*. **370**, 1227–1230 (2020).
- 815 26. C. Feng, J. Shi, Q. Fan, Y. Wang, H. Huang, F. Chen, G. Tang, Y. Li, P. Li, J. Li, J. Cui, L.  
816 Guo, S. Chen, M. Jiang, L. Feng, L. Chen, C. Lei, C. Ke, X. Deng, F. Hu, X. Tang, F. Li,  
817 Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year  
818 after recovery. *Nat Commun*. **12**, 4984 (2021).
- 819 27. G. Rijkers, J.-L. Murk, B. Wintermans, B. van Looy, M. van den Berge, J. Veenemans, J.  
820 Stohr, C. Reusken, P. van der Pol, J. Reimerink, Differences in Antibody Kinetics and  
821 Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2  
822 Infections. *J Infect Dis*, jiaa463 (2020).
- 823 28. C. Rydyznski Moderbacher, S. I. Ramirez, J. M. Dan, A. Grifoni, K. M. Hastie, D.  
824 Weiskopf, S. Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E. G. Crotty, C. Kim, S. A.  
825 Rawlings, J. Mateus, L. P. V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E.  
826 Ollmann Saphire, D. M. Smith, A. Sette, S. Crotty, Antigen-Specific Adaptive Immunity to  
827 SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*.  
828 **183**, 996-1012.e19 (2020).
- 829 29. F. Tea, A. O. Stella, A. Aggarwal, D. R. Darley, D. Pilli, D. Vitale, V. Merheb, F. X. Z.  
830 Lee, P. Cunningham, G. J. Walker, C. Fichter, D. A. Brown, W. D. Rawlinson, S. R. Isaacs,  
831 V. Mathivanan, M. Hoffmann, S. Pöhlman, O. Mazigi, D. Christ, D. E. Dwyer, R. J.

- 832 Rockett, V. Sintchenko, V. C. Hoad, D. O. Irving, G. J. Dore, I. B. Gosbell, A. D. Kelleher,  
833 G. V. Matthews, F. Brilot, S. G. Turville, SARS-CoV-2 neutralizing antibodies: Longevity,  
834 breadth, and evasion by emerging viral variants. *PLOS Medicine*. **18**, e1003656 (2021).
- 835 30. K. Röltgen, A. E. Powell, O. F. Wirz, B. A. Stevens, C. A. Hogan, J. Najeeb, M. Hunter, H.  
836 Wang, M. K. Sahoo, C. Huang, F. Yamamoto, M. Manohar, J. Manalac, A. R. Otrelo-  
837 Cardoso, T. D. Pham, A. Rustagi, A. J. Rogers, N. H. Shah, C. A. Blish, J. R. Cochran, T.  
838 S. Jardetzky, J. L. Zehnder, T. T. Wang, B. Narasimhan, S. Gombar, R. Tibshirani, K. C.  
839 Nadeau, P. S. Kim, B. A. Pinsky, S. D. Boyd, Defining the features and duration of  
840 antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.  
841 *Sci Immunol*. **5**, eabe0240 (2020).
- 842 31. J. Zhang, H. Lin, B. Ye, M. Zhao, J. Zhan, S. Dong, Y. Guo, Y. Zhao, M. Li, S. Liu, H.  
843 Zhang, W. Xiao, Y. Guo, C. Yue, D. Zhang, M. Yang, J. Zhang, C. Quan, W. Shi, X. Liu,  
844 P. Liu, Y. Jiang, G. Wu, G. F. Gao, W. J. Liu, One-year sustained cellular and humoral  
845 immunities of COVID-19 convalescents. *Clin Infect Dis*, ciab884 (2021).
- 846 32. S. Glöckner, F. Hornung, M. Baier, S. Weis, M. W. Pletz, S. Deinhardt-Emmer, B. Löffler,  
847 the CoNAN Study Group, Robust Neutralizing Antibody Levels Detected after Either  
848 SARS-CoV-2 Vaccination or One Year after Infection. *Viruses*. **13**, 2003 (2021).
- 849 33. S. F. Lumley, D. O'Donnell, N. E. Stoesser, P. C. Matthews, A. Howarth, S. B. Hatch, B.  
850 D. Marsden, S. Cox, T. James, F. Warren, L. J. Peck, T. G. Ritter, Z. de Toledo, L. Warren,  
851 D. Axten, R. J. Cornall, E. Y. Jones, D. I. Stuart, G. Screaton, D. Ebner, S. Hoosdally, M.  
852 Chand, D. W. Crook, A.-M. O'Donnell, C. P. Conlon, K. B. Pouwels, A. S. Walker, T. E.  
853 A. Peto, S. Hopkins, T. M. Walker, K. Jeffery, D. W. Eyre, Antibody Status and Incidence

- 854 of SARS-CoV-2 Infection in Health Care Workers. *New England Journal of Medicine*  
855 (2020), doi:10.1056/NEJMoa2034545.
- 856 34. Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.-H.  
857 Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. Da  
858 Silva, E. Bednarski, L. Aguado, J. Yee, M. Daga, M. Turroja, K. G. Millard, M. Jankovic,  
859 A. Gazumyan, Z. Zhao, C. M. Rice, P. D. Bieniasz, M. Caskey, T. Hatziioannou, M. C.  
860 Nussenzweig, Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after  
861 infection. *Nature*. **595**, 426–431 (2021).
- 862 35. L. Yao, G.-L. Wang, Y. Shen, Z.-Y. Wang, B.-D. Zhan, L.-J. Duan, B. Lu, C. Shi, Y.-M.  
863 Gao, H.-H. Peng, G.-Q. Wang, D.-M. Wang, M.-D. Jiang, G.-P. Cao, M.-J. Ma, Persistence  
864 of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after  
865 Infection. *J Infect Dis*, jia255 (2021).
- 866 36. J. S. Turner, W. Kim, E. Kalaidina, C. W. Goss, A. M. Rauseo, A. J. Schmitz, L. Hansen,  
867 A. Haile, M. K. Klebert, I. Pusic, J. A. O’Halloran, R. M. Presti, A. H. Ellebedy, SARS-  
868 CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature*. **595**,  
869 421–425 (2021).
- 870 37. K. Vanshylla, V. Di Cristanziano, F. Kleipass, F. Dewald, P. Schommers, L. Gieselmann,  
871 H. Gruell, M. Schlotz, M. S. Ercanoglu, R. Stumpf, P. Mayer, M. Zehner, E. Heger, W.  
872 Johannis, C. Horn, I. Suárez, N. Jung, S. Salomon, K. A. Eberhardt, B. Gathof, G.  
873 Fätkenheuer, N. Pfeifer, R. Eggeling, M. Augustin, C. Lehmann, F. Klein, Kinetics and  
874 correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. *Cell*  
875 *Host & Microbe*. **29**, 917-929.e4 (2021).

- 876 38. C. Manisty, T. A. Treibel, M. Jensen, A. Semper, G. Joy, R. K. Gupta, T. Cutino-Moguel,  
877 M. Andiapan, J. Jones, S. Taylor, A. Otter, C. Pade, J. Gibbons, J. Lee, J. Bacon, S.  
878 Thomas, C. Moon, M. Jones, D. Williams, J. Lambourne, M. Fontana, D. M. Altmann, R.  
879 Boyton, M. Maini, A. McKnight, B. Chain, M. Noursadeghi, J. C. Moon, Time series  
880 analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody  
881 responses to mild SARS-CoV-2 infection. *EBioMedicine*. **65** (2021),  
882 doi:10.1016/j.ebiom.2021.103259.
- 883 39. P. G. Choe, C. K. Kang, H. J. Suh, J. Jung, K.-H. Song, J. H. Bang, E. S. Kim, H. B. Kim,  
884 S. W. Park, N. J. Kim, W. B. Park, M. Oh, Waning Antibody Responses in Asymptomatic  
885 and Symptomatic SARS-CoV-2 Infection. *Emerg Infect Dis*. **27**, 327–329 (2021).
- 886 40. Q.-X. Long, X.-J. Tang, Q.-L. Shi, Q. Li, H.-J. Deng, J. Yuan, J.-L. Hu, W. Xu, Y. Zhang,  
887 F.-J. Lv, K. Su, F. Zhang, J. Gong, B. Wu, X.-M. Liu, J.-J. Li, J.-F. Qiu, J. Chen, A.-L.  
888 Huang, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.  
889 *Nat Med*. **26**, 1200–1204 (2020).
- 890 41. Q. Lei, Y. Li, H. Hou, F. Wang, Z. Ouyang, Y. Zhang, D. Lai, J.-L. Banga Ndzouboukou,  
891 Z. Xu, B. Zhang, H. Chen, J. Xue, X. Lin, Y. Zheng, Z. Yao, X. Wang, C. Yu, H. Jiang, H.  
892 Zhang, H. Qi, S. Guo, S. Huang, Z. Sun, S. Tao, X. Fan, Antibody dynamics to SARS-  
893 CoV-2 in asymptomatic COVID-19 infections. *Allergy*. **76**, 551–561 (2021).
- 894 42. F. J. Ibarondo, J. A. Fulcher, D. Goodman-Meza, J. Elliott, C. Hofmann, M. A. Hausner,  
895 K. G. Ferbas, N. H. Tobin, G. M. Aldrovandi, O. O. Yang, Rapid Decay of Anti-SARS-  
896 CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med* (2020),  
897 doi:10.1056/NEJMc2025179.



- 898 43. S. Schwarzkopf, A. Krawczyk, D. Knop, H. Klump, A. Heinold, F. M. Heinemann, L.  
899 Thümmeler, C. Temme, M. Breyer, O. Witzke, U. Dittmer, V. Lenz, P. A. Horn, M.  
900 Lindemann, Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed  
901 Infection but with Undetectable SARS-CoV-2-Specific IgG - Volume 27, Number 1—  
902 January 2021 - Emerging Infectious Diseases journal - CDC, doi:10.3201/eid2701.203772.
- 903 44. D. Weiskopf, K. S. Schmitz, M. P. Raadsen, A. Grifoni, N. M. A. Okba, H. Endeman, J. P.  
904 C. van den Akker, R. Molenkamp, M. P. G. Koopmans, E. C. M. van Gorp, B. L.  
905 Haagmans, R. L. de Swart, A. Sette, R. D. de Vries, Phenotype and kinetics of SARS-CoV-  
906 2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci*  
907 *Immunol.* **5**, eabd2071 (2020).
- 908 45. C. Fenwick, A. Croxatto, A. T. Coste, F. Pojer, C. André, C. Pellaton, A. Farina, J.  
909 Campos, D. Hacker, K. Lau, B.-J. Bosch, S. G. Nussle, M. Bochud, V. D’Acremont, D.  
910 Trono, G. Greub, G. Pantaleo, Changes in SARS-CoV-2 Spike versus Nucleoprotein  
911 Antibody Responses Impact the Estimates of Infections in Population-Based  
912 Seroprevalence Studies. *J. Virol.* **95**, e01828-20 (2021).
- 913 46. C. Genolini, X. Alacoque, M. Sentenac, C. Arnaud, kml and kml3d: R Packages to Cluster  
914 Longitudinal Data. *Journal of Statistical Software.* **65**, 1–34 (2015).
- 915 47. C. Genolini, J. B. Pingault, T. Driss, S. Côté, R. E. Tremblay, F. Vitaro, C. Arnaud, B.  
916 Falissard, KmL3D: A non-parametric algorithm for clustering joint trajectories. *Computer*  
917 *Methods and Programs in Biomedicine.* **109**, 104–111 (2013).
- 918 48. T. Takahashi, M. K. Ellingson, P. Wong, B. Israelow, C. Lucas, J. Klein, J. Silva, T. Mao,  
919 J. E. Oh, M. Tokuyama, P. Lu, A. Venkataraman, A. Park, F. Liu, A. Meir, J. Sun, E. Y.  
920 Wang, A. Casanovas-Massana, A. L. Wyllie, C. B. F. Vogels, R. Earnest, S. Lapidus, I. M.

- 921 Ott, A. J. Moore, A. Shaw, J. B. Fournier, C. D. Odio, S. Farhadian, C. D. Cruz, N. D.  
922 Grubaugh, W. L. Schulz, A. M. Ring, A. I. Ko, S. B. Omer, A. Iwasaki, Sex differences in  
923 immune responses that underlie COVID-19 disease outcomes. *Nature*. **588**, 315–320  
924 (2020).
- 925 49. J. Wei, P. C. Matthews, N. Stoesser, T. Maddox, L. Lorenzi, R. Studley, J. I. Bell, J. N.  
926 Newton, J. Farrar, I. Diamond, E. Rourke, A. Howarth, B. D. Marsden, S. Hoosdally, E. Y.  
927 Jones, D. I. Stuart, D. W. Crook, T. E. A. Peto, K. B. Pouwels, A. S. Walker, D. W. Eyre,  
928 Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.  
929 *Nat Commun*. **12**, 6250 (2021).
- 930 50. L. Piccoli, Y.-J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M. Beltramello, C.  
931 Silacci-Fregni, D. Pinto, L. E. Rosen, J. E. Bowen, O. J. Acton, S. Jaconi, B. Guarino, A.  
932 Minola, F. Zatta, N. Sprugasci, J. Bassi, A. Peter, A. De Marco, J. C. Nix, F. Mele, S. Jovic,  
933 B. F. Rodriguez, S. V. Gupta, F. Jin, G. Piumatti, G. Lo Presti, A. F. Pellanda, M.  
934 Biggiogero, M. Tarkowski, M. S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M.  
935 Smithey, D. Hong, V. Lepori, E. Albanese, A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C.  
936 Garzoni, A. Riva, G. Snell, F. Sallusto, K. Fink, H. W. Virgin, A. Lanzavecchia, D. Corti,  
937 D. Veessler, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike  
938 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell*. **183**, 1024-  
939 1042.e21 (2020).
- 940 51. K. W. Cohen, S. L. Linderman, Z. Moodie, J. Czartoski, L. Lai, G. Mantus, C. Norwood, L.  
941 E. Nyhoff, V. V. Edara, K. Floyd, S. C. D. Rosa, H. Ahmed, R. Whaley, S. N. Patel, B.  
942 Prigmore, M. P. Lemos, C. W. Davis, S. Furth, J. O’Keefe, M. P. Gharpure, S. Gunisetty,  
943 K. A. Stephens, R. Antia, V. I. Zarnitsyna, D. S. Stephens, S. Edupuganti, N. Roupheal, E.

- 944 J. Anderson, A. K. Mehta, J. Wrammert, M. S. Suthar, R. Ahmed, M. J. McElrath, in press,  
945 doi:10.1101/2021.04.19.21255739.
- 946 52. W. S. Lee, K. J. Selva, S. K. Davis, B. D. Wines, A. Reynaldi, R. Esterbauer, H. G. Kelly,  
947 E. R. Haycroft, H.-X. Tan, J. A. Juno, A. K. Wheatley, P. M. Hogarth, D. Cromer, M. P.  
948 Davenport, A. W. Chung, S. J. Kent, Decay of Fc-dependent antibody functions after mild  
949 to moderate COVID-19. *Cell Reports Medicine*. **2**, 100296 (2021).
- 950 53. L. Premkumar, B. Segovia-Chumbez, R. Jadi, D. R. Martinez, R. Raut, A. Markmann, C.  
951 Cornaby, L. Bartelt, S. Weiss, Y. Park, C. E. Edwards, E. Weimer, E. M. Scherer, N.  
952 Rouphael, S. Edupuganti, D. Weiskopf, L. V. Tse, Y. J. Hou, D. Margolis, A. Sette, M. H.  
953 Collins, J. Schmitz, R. S. Baric, A. M. de Silva, The receptor binding domain of the viral  
954 spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-  
955 2 patients. *Sci Immunol*. **5**, eabc8413 (2020).
- 956 54. J. H. Jung, M.-S. Rha, M. Sa, H. K. Choi, J. H. Jeon, H. Seok, D. W. Park, S.-H. Park, H.  
957 W. Jeong, W. S. Choi, E.-C. Shin, SARS-CoV-2-specific T cell memory is sustained in  
958 COVID-19 convalescent patients for 10 months with successful development of stem cell-  
959 like memory T cells. *Nat Commun*. **12**, 4043 (2021).
- 960 55. J. Neidleman, X. Luo, J. Frouard, G. Xie, G. Gill, E. S. Stein, M. McGregor, T. Ma, A. F.  
961 George, A. Kusters, W. C. Greene, J. Vasquez, E. Ghosn, S. Lee, N. R. Roan, SARS-CoV-  
962 2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal  
963 Differentiation, and High Proliferation Potential. *Cell Reports Medicine*. **1**, 100081 (2020).
- 964 56. H. Hou, Y. Zhang, G. Tang, Y. Luo, W. Liu, C. Cheng, Y. Jiang, Z. Xiong, S. Wu, Z. Sun,  
965 S. Xu, X. Fan, F. Wang, Immunologic memory to SARS-CoV-2 in convalescent COVID-

- 966 19 patients at 1 year postinfection. *Journal of Allergy and Clinical Immunology*. **0** (2021),  
967 doi:10.1016/j.jaci.2021.09.008.
- 968 57. Y. Peng, A. J. Mentzer, G. Liu, X. Yao, Z. Yin, D. Dong, W. Dejnirattisai, T. Rostron, P.  
969 Supasa, C. Liu, C. López-Camacho, J. Slon-Campos, Y. Zhao, D. I. Stuart, G. C. Paesen, J.  
970 M. Grimes, A. A. Antson, O. W. Bayfield, D. E. D. P. Hawkins, D.-S. Ker, B. Wang, L.  
971 Turtle, K. Subramaniam, P. Thomson, P. Zhang, C. Dold, J. Ratcliff, P. Simmonds, T. de  
972 Silva, P. Sopp, D. Wellington, U. Rajapaksa, Y.-L. Chen, M. Salio, G. Napolitani, W. Paes,  
973 P. Borrow, B. M. Kessler, J. W. Fry, N. F. Schwabe, M. G. Semple, J. K. Baillie, S. C.  
974 Moore, P. J. M. Openshaw, M. A. Ansari, S. Dunachie, E. Barnes, J. Frater, G. Kerr, P.  
975 Goulder, T. Lockett, R. Levin, Y. Zhang, R. Jing, L.-P. Ho, R. J. Cornall, C. P. Conlon, P.  
976 Klenerman, G. R. Screaton, J. Mongkolsapaya, A. McMichael, J. C. Knight, G. Ogg, T.  
977 Dong, Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-CoV-2 in UK  
978 convalescent individuals following COVID-19. *Nat Immunol*. **21**, 1336–1345 (2020).
- 979 58. ISRCTN14990068: Zurich Coronavirus Cohort: an observational study to determine long-  
980 term clinical outcomes and immune responses after coronavirus infection (COVID-19),  
981 assess the influence of virus genetics, and examine the spread of the coronavirus in the  
982 population of the Canton of Zurich, Switzerland. *ISRCTN Registry* (2020),  
983 doi:10.1186/ISRCTN14990068.
- 984 59. A. L. Whitcombe, R. McGregor, A. Craigie, A. James, R. Charlewood, N. Lorenz, J. M.  
985 Dickson, C. R. Sheen, B. Koch, S. Fox-Lewis, G. McAuliffe, S. A. Roberts, S. C. Morpeth,  
986 S. Taylor, R. H. Webb, S. Jack, A. Upton, J. E. Ussher, N. J. Moreland, Comprehensive  
987 analysis of SARS-CoV-2 antibody dynamics in New Zealand. *Clin Transl Immunology*. **10**,  
988 e1261 (2021).

- 989 60. M. Poehler, L. Gibson, A. Lustig, N. J. Moreland, R. McGregor, A. James, in press,  
990 doi:10.1101/2021.06.13.21258857.
- 991 61. S. M. Kaech, W. Cui, Transcriptional control of effector and memory CD8+ T cell  
992 differentiation. *Nat Rev Immunol.* **12**, 749–761 (2012).
- 993 62. R Core Team, R: A language and environment for statistical computing. R Foundation for  
994 Statistical Computing. *Vienna, Austria* (2021), (available at <https://www.R-project.org/>).

995

996 **Acknowledgments:** The authors would like to thank the study administration team and the study  
997 participants for their dedicated contribution to this research project.

998 **Funding:** This study is part of Corona Immunitas research network, coordinated by the Swiss  
999 School of Public Health (SSPH+), and funded by fundraising of SSPH+ that includes  
1000 funds of the Swiss Federal Office of Public Health and private funders (ethical guidelines  
1001 for funding stated by SSPH+ will be respected), by funds of the Cantons of Switzerland  
1002 (Vaud, Zurich, and Basel) and by institutional funds of the Universities. Additional  
1003 funding, specific to this study was received from the Department of Health of the Canton  
1004 of Zurich, the University of Zurich Foundation, and the Swiss Federal Office of Public  
1005 Health. The funding bodies had no influence on the study design or the conduct, analysis,  
1006 or interpretation of the study findings. TB received funding from the European Union’s  
1007 Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie  
1008 grant agreement No 801076, through the SSPH+ Global PhD Fellowship Programme in  
1009 Public Health Sciences (GlobalP3HS) of the SSPH+. HA received an Swiss National  
1010 Science Foundation (SNSF) Early Postdoc.Mobility Fellowship.

1011

1012 **Author contributions:**

1013 Conceptualization: DM, KDZ, TB, CM, MAP, JSF

1014 Methodology: DM, KDZ, TB, NC, CP, MP, CF, GP, CM, MAP, JSF

1015 Investigation: DM, KDZ, TB, NC, CP, MP, CF, GP, CRK

1016 Visualization: DM, KDZ, TB, NC

1017 Funding acquisition: MAP, JSF

1018 Project administration: DM, TB, HEA, AD, MAP

1019 Supervision: CM, MAP, JSF

1020 Writing – original draft: DM, KDZ, TB

1021 Writing – review & editing: DM, KDZ, TB, NC, DLC, HEA, AD, CP, MP, CF, GP, CRK,

1022 CM, MAP, JSF

1023

1024 **Competing interests:** The authors declare that they have no competing interests.

1025 **Data and materials availability:** All data are available in the main text or the supplementary


1026 materials.

1027

1028


1029 **Figures:**

1030



1031 **Fig. 1. Study design and population characteristics.** (A) Figure showing the overall study  
1032 design, assessments conducted on and baseline clinical characteristics of all enrolled  
1033 participants (n=431). (B) Figure showing the assessments conducted on and clinical  
1034 characteristics of a randomly selected subsample of participants covering the full range of  
1035 the infected population (n=64).

1036



1037 **Fig. 2. Anti-SARS-CoV-2 S-IgA, S-IgG, N-IgG-specific antibody responses over time. (A)**

1038 Scatter and distributional plots demonstrating the measured mean fluorescence intensity

1039 (MFI) ratios for anti-S-IgA antibodies in the overall study population (n=431), overall

1040 and stratified by age groups and sex. MFI: mean fluorescence intensity, W2: two weeks,

1041 M1: one month, M3: three months, M6: six months after diagnosis. (B) Scatter and

1042 distributional plots of measured MFI ratios for anti-S-IgG antibodies in the overall study

1043 population (n=431), overall and stratified by age groups and sex. (C) Scatter and


1044 distributional plots of measured MFI ratios for anti-S-IgG antibodies within the

1045 subsample of individuals undergoing detailed testing (n=64), overall and stratified by age

1046 groups and sex. (D) Anti-S-IgA antibody decay estimation based on mixed linear




1047 regression model. Adj.  $t_{1/2}$ : half-life based on model adjusted for time from diagnosis to  
 1048 maximum MFI ratio, age group, sex and symptom count, using a random intercept for  
 1049 each individual in the study. (E) Anti-S-IgG antibody decay estimation based on mixed  
 1050 linear regression mode. (F) Anti-N-IgG antibody decay estimation within the subsample,  
 1051 based on mixed linear regression model.  
 1052



1053 **Fig. 3. M-, N-, S1- and S2-specific T cell responses over time.** (A) Number of T cells  
 1054 responding to M, N, S1 or S2 overlapping peptide pools per 1e6 PBMCs by day post-  
 1055 diagnosis. (B) Fraction of the total T cell response specific for each peptide pool at

1056 indicated timepoints post-diagnosis. Spec. TC: specific T cells, W2: two weeks, M1: one  
 1057 month, M3: three months, M6: six months after diagnosis. (C) Representative flow  
 1058 cytometry plots depicting AIM<sup>+</sup> (CD134<sup>+</sup>CD137<sup>+</sup>) CD4<sup>+</sup> (left) and (CD69<sup>+</sup>CD137<sup>+</sup>)  
 1059 CD8<sup>+</sup> (right) populations in unstimulated (top) or pooled SARS-CoV-2 peptide-  
 1060 stimulated (bottom) PBMCs. (D) AIM<sup>+</sup> cells as a fraction of CD4<sup>+</sup> or CD8<sup>+</sup> T cells at  
 1061 indicated timepoints post-diagnosis. Horizontal lines represent mean at timepoint. (E)  
 1062 Percentage of CD4<sup>+</sup> or CD8<sup>+</sup> AIM<sup>+</sup> T cells with TCM (CD45RA<sup>-</sup>CCR7<sup>+</sup>), TEM  
 1063 (CD45RA<sup>-</sup>CCR7<sup>-</sup>) or TEMRA (CD45RA<sup>+</sup>CCR7<sup>-</sup>) phenotypes by day post-diagnosis.

1064



1065 **Fig. 4. Relationship between antibody and T cell responses over time. (A)** Heatmaps


1066 demonstrating the correlation between anti-S-IgA and IgG and anti-N-IgG antibody

1067 subtypes and M-, N-, S1- and S2-specific T cells at the different timepoints. Numbers in

1068 individual cells correspond to the Spearman correlation coefficient. W2: two weeks, M1:

1069 one month, M3: three months, M6: six months after diagnosis. (B) Panel demonstrating


1070 the proportion of participants with concordant and discordant results between anti-S-IgA,  
 1071 anti-S-IgG and anti-N-IgG antibody subtypes and overall T cell positivity over time.  
 1072



1073 **Fig. 5. Clustering of antibody and T cell response trajectories.** (A) Panel demonstrating the  
 1074 mean MFI ratios of anti-S-IgA, anti-S-IgG and anti-N-IgG antibodies and mean M-, N-,  
 1075 S1-, and S-specific T cells/1e6 PBMCs in each of the five clusters over time. Displayed

1076 data was natural logarithm-transformed and normalized. W2: two weeks, M1: one month,  
1077 M3: three months, M6: six months after diagnosis. **(B)** Heatmap showing the MFI ratios  
1078 of anti-S-IgA, anti-S-IgG and anti-N antibodies and M-, N-, S1-, and S-specific T  
1079 cells/1e6 PBMCs for all participants belonging to the identified clusters 1 to 5. Gray  
1080 color indicates missing values. **(C)** Dot plots of anti-S-IgG MFI ratio, N-specific T  
1081 cells/1e6 PBMCs, S-specific T cells/1e6 PBMCs and frequency of AIM<sup>+</sup> of CD4<sup>+</sup> T cells  
1082 in the five clusters over time. Horizontal lines represent mean at timepoint. **(D)** Bar plot  
1083 showing the proportion of participants according belonging to different age groups (18-  
1084 39 years, 40-64 years, ≥65 years), sex (male and female), smoking status (non-smoker,  
1085 ex-smoker, smoker), number of symptoms reported (asymptomatic, 1-5 symptoms, ≥6  
1086 symptoms), and hospitalization status (non-hospitalized, hospitalized) during acute  
1087 infection. Asymp.: asymptomatic, symp.: symptoms, hosp.: hospitalized.  
1088

1089



1090 **Fig. 6. Association analyses of antibody and T cell responses.** (A) Forest plot demonstrating  
 1091 results from adjusted mixed linear regression analyses evaluating the associations of anti-  
 1092 S-IgA MFI ratios with demographic and clinical factors (age, sex, COVID-19 symptom  
 1093 count, smoking status, body mass index, presence of at least one comorbidity and  
 1094 immunosuppression) in the overall study population (n=431). Model was adjusted for  
 1095 time since diagnosis, age group, sex, and disease severity expressed as symptom count,  
 1096 with a random intercept for each individual. BMI: body mass index. (B) Forest plot  
 1097 showing results from adjusted mixed linear regression analyses evaluating the  
 1098 associations of anti-S-IgG MFI ratios with demographic and clinical factors. Model

1099 adjustment as for panel A. **(C)** Forest plot showing results from adjusted mixed linear  
1100 regression analyses evaluating the associations of anti-N-IgG MFI ratios with  
1101 demographic and clinical factors in the subsample (n=64). Model adjustment as for panel  
1102 A. **(D)** Forest plot demonstrating results from adjusted mixed linear regression analyses  
1103 evaluating the associations of overall T cell counts per 1e6 PBMCs with demographic  
1104 and clinical factors in the subsample (n=64). Model adjustment as for panel A.